

Francesco Marampon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2676307/publications.pdf>

Version: 2024-02-01

84
papers

2,631
citations

136740

32
h-index

223531

46
g-index

86
all docs

86
docs citations

86
times ranked

4599
citing authors

#	ARTICLE	IF	CITATIONS
1	ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma. <i>Cancers</i> , 2022, 14, 289.	1.7	10
2	The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 852941.	1.6	7
3	MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression. <i>Frontiers in Oncology</i> , 2022, 12, 835642.	1.3	5
4	Recommendation for the contouring of limbic system in patients receiving radiation treatment: A pictorial review for the everyday practice and education. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103229.	2.0	4
5	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2894.	1.8	9
6	OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence. <i>Cancers</i> , 2021, 13, 1519.	1.7	7
7	Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair. <i>Cancer Letters</i> , 2021, 505, 1-12.	3.2	21
8	Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts. <i>Biology</i> , 2021, 10, 491.	1.3	7
9	Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in Vitro and in Vivo, the alveolar phenotype subtype. <i>International Journal of Radiation Biology</i> , 2021, 97, 943-957.	1.0	13
10	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10671.	1.8	14
11	Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma. <i>Pharmaceuticals</i> , 2021, 14, 1082.	1.7	4
12	Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. <i>Journal of Biomedical Science</i> , 2020, 27, 90.	2.6	18
13	The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties. <i>Frontiers in Pharmacology</i> , 2020, 11, 552428.	1.6	17
14	One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 124-130.	0.4	5
15	Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines <i>in Vitro</i> and <i>in Vivo</i> . <i>Journal of Oncology</i> , 2020, 2020, 1-16.	0.6	9
16	The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 61-66.	0.4	10
17	A New Threat to Dopamine Neurons: The Downside of Artificial Light. <i>Neuroscience</i> , 2020, 432, 216-228.	1.1	13
18	Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation. <i>International Journal of Radiation Biology</i> , 2020, 96, 823-835.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients. <i>Current Treatment Options in Oncology</i> , 2020, 21, 1.	1.3	27
20	BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells. <i>Cancer Letters</i> , 2020, 479, 71-88.	3.2	15
21	Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease. <i>Current Pharmaceutical Design</i> , 2020, 25, 4510-4522.	0.9	17
22	Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 183-197.	1.8	5
23	Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. <i>Cancer Letters</i> , 2019, 461, 90-101.	3.2	22
24	The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. <i>Cancers</i> , 2019, 11, 1604.	1.7	11
25	NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 881-893.	1.2	28
26	Parkinson's disease and light: The bright and the Dark sides. <i>Brain Research Bulletin</i> , 2019, 150, 290-296.	1.4	10
27	Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study. <i>Current Problems in Cancer</i> , 2019, 43, 495-503.	1.0	3
28	Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2530.	1.8	47
29	Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 75-82.	2.0	2
30	The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. <i>Cancers</i> , 2019, 11, 359.	1.7	42
31	Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation. <i>Cancer Letters</i> , 2019, 449, 135-144.	3.2	17
32	Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 393-409.	1.2	25
33	PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 137-152.	1.2	25
34	Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1717-1730.	1.2	56
35	Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1685-1699.	1.2	40
36	Cellular and Molecular Mediators of Bone Metastatic Lesions. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1709.	1.8	15

#	ARTICLE	IF	CITATIONS
37	The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 32.	6.9	24
38	Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. <i>Oncotarget</i> , 2018, 9, 33702-33709.	0.8	6
39	Oral Platelet Gel Supernatant Plus Supportive Medical Treatment Versus Supportive Medical Treatment in the Management of Radiation-induced Oral Mucositis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 336-341.	0.6	12
40	The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 5.	6.9	56
41	The First Negative Allosteric Modulator for Dopamine D ₂ and D ₃ Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs. <i>Molecular Pharmacology</i> , 2017, 91, 586-594.	1.0	33
42	HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. <i>Cancer Letters</i> , 2017, 397, 1-11.	3.2	72
43	The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. <i>Tumor Biology</i> , 2017, 39, 101042831769552.	0.8	44
44	Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. <i>Journal of Hematology and Oncology</i> , 2017, 10, 161.	6.9	29
45	Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models. <i>Oncotarget</i> , 2017, 8, 29865-29886.	0.8	12
46	Defective DNA repair mechanisms in prostate cancer: impact of olaparib. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 547-552.	2.0	26
47	Radiation therapy and serum salivary amylase in head and neck cancer. <i>Oncotarget</i> , 2017, 8, 90496-90500.	0.8	10
48	The possible prognostic role of histone deacetylase and transforming growth factor β /Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study. <i>European Journal of Histochemistry</i> , 2017, 61, 2732.	0.6	24
49	Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer. <i>Oncotarget</i> , 2017, 8, 111225-111245.	0.8	16
50	Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy. <i>Oncotarget</i> , 2017, 8, 113792-113806.	0.8	7
51	Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer. <i>Oncology Reports</i> , 2016, 36, 125-130.	1.2	9
52	Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: A retrospective study by propensity analysis. <i>Oncology Letters</i> , 2016, 11, 1948-1954.	0.8	13
53	Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. <i>Molecular Cancer</i> , 2016, 15, 16.	7.9	75
54	Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. <i>Tumor Biology</i> , 2016, 37, 341-351.	0.8	22

#	ARTICLE	IF	CITATIONS
55	Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results. <i>Oncotarget</i> , 2016, 7, 80077-80082.	0.8	9
56	DNMT3B <i>in vitro</i> knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation. <i>Oncotarget</i> , 2016, 7, 79342-79356.	0.8	37
57	Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. <i>Oncotarget</i> , 2016, 7, 5383-5400.	0.8	53
58	KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. <i>BMC Cancer</i> , 2015, 15, 941.	1.1	50
59	Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 Patients. <i>PLoS ONE</i> , 2015, 10, e0129021.	1.1	42
60	Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. <i>Prostate</i> , 2014, 74, 852-868.	1.2	35
61	Intravesical instillations with polydeoxyribonucleotides reduce symptoms of radiation-induced cystitis in patients treated with radiotherapy for pelvic cancer: a pilot study. <i>Supportive Care in Cancer</i> , 2014, 22, 1155-1159.	1.0	9
62	Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. <i>International Journal of Oncology</i> , 2014, 44, 285-294.	1.4	43
63	Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1 α functional interplay. <i>International Journal of Oncology</i> , 2014, 44, 2121-2131.	1.4	64
64	Topical application of platelet supernatant gel in the management of radiotherapy-induced mucositis: a case report. <i>Blood Transfusion</i> , 2014, 12, 107-110.	0.3	3
65	Vitamin D Protects Human Endothelial Cells from H ₂ O ₂ Oxidant Injury Through the Mek/Erk-Sirt1 Axis Activation. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 221-231.	1.1	119
66	Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. <i>International Journal of Oncology</i> , 2013, 42, 2116-2122.	1.4	33
67	PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, 321-337.	1.6	43
68	Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis. <i>Journal of Hypertension</i> , 2013, 31, 1972-1983.	0.3	41
69	Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. <i>Oncology Reports</i> , 2013, 29, 1189-1195.	1.2	55
70	Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. <i>International Journal of Oncology</i> , 2011, 40, 711-720.	1.4	27
71	A feasibility study of percutaneous radiofrequency ablation followed by radiotherapy in the management of painful osteolytic bone metastases. <i>European Radiology</i> , 2011, 21, 2004-2010.	2.3	81
72	Antitumor effects of carnitinib in castration resistant prostate cancer models: A comparative study with erlotinib. <i>Prostate</i> , 2011, 71, 1481-1491.	1.2	8

#	ARTICLE	IF	CITATIONS
73	Hormonal Therapy Promotes Hormone-Resistant Phenotype by Increasing DNMT Activity and Expression in Prostate Cancer Models. <i>Endocrinology</i> , 2011, 152, 4550-4561.	1.4	48
74	MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells <i>in vitro</i> and <i>in vivo</i> by Downregulating Growth and DNA Repair Signals. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 159-168.	1.9	78
75	The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2011, 18, 385-400.	1.6	35
76	5-azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. <i>Prostate</i> , 2010, 70, 1166-1178.	1.2	41
77	Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. <i>Molecular Cancer</i> , 2010, 9, 305.	7.9	113
78	MEK/ERK inhibitor U0126 affects <i>in vitro</i> and <i>in vivo</i> growth of embryonal rhabdomyosarcoma. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 543-551.	1.9	89
79	Nerve Growth Factor Regulation of Cyclin D1 in PC12 Cells through a p21 ^{RAS} Extracellular Signal-regulated Kinase Pathway Requires Cooperative Interactions between Sp1 and Nuclear Factor- κ B. <i>Molecular Biology of the Cell</i> , 2008, 19, 2566-2578.	0.9	44
80	Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. <i>Cell Cycle</i> , 2008, 7, 1870-1879.	1.3	81
81	ROCK2 and Its Alternatively Spliced Isoform ROCK2m Positively Control the Maturation of the Myogenic Program. <i>Molecular and Cellular Biology</i> , 2007, 27, 6163-6176.	1.1	46
82	HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers. <i>Experimental Cell Research</i> , 2006, 312, 1590-1597.	1.2	15
83	Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. <i>Molecular Cancer</i> , 2006, 5, 31.	7.9	129
84	p21 ^{WAF1} expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. <i>Molecular Cancer</i> , 2005, 4, 41.	7.9	63